| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6287594 | ASSERTIO | Oral liquid compositions |
Jan, 2019
(5 years ago) | |
| US6365180 | ASSERTIO | Oral liquid compositions |
Jul, 2019
(4 years ago) | |
| US9561200 | ASSERTIO | Method of treating post-surgical acute pain |
Feb, 2029
(4 years from now) | |
| US8623920 | ASSERTIO | Method of treating post-surgical acute pain |
Feb, 2029
(4 years from now) | |
| US8110606 | ASSERTIO | Method of treating post-surgical acute pain |
Feb, 2029
(4 years from now) | |
| US7884095 | ASSERTIO | Method of treating post-surgical acute pain |
Feb, 2029
(4 years from now) | |
| US7662858 | ASSERTIO | Method of treating post-surgical acute pain |
Feb, 2029
(4 years from now) | |
| US7939518 | ASSERTIO | Method of treating post-surgical acute pain |
Feb, 2029
(4 years from now) | |
Zipsor is owned by Assertio.
Zipsor contains Diclofenac Potassium.
Zipsor has a total of 8 drug patents out of which 2 drug patents have expired.
Expired drug patents of Zipsor are:
- US6287594
- US6365180
Zipsor was authorised for market use on 16 June, 2009.
Zipsor is available in capsule;oral dosage forms.
Zipsor can be used as nonsteroidal anti-inflammatory drug indicated for relief of mild to moderate acute pain, diclofenac potassium for relief of mild to moderate acute pain.
The generics of Zipsor are possible to be released after 24 February, 2029.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | May 25, 2024 |
| New Dosage Form(NDF) | Jun 16, 2012 |
Drugs and Companies using DICLOFENAC POTASSIUM ingredient
Market Authorisation Date: 16 June, 2009
Treatment: Nonsteroidal anti-inflammatory drug indicated for relief of mild to moderate acute pain; Diclofenac potassium for relief of mild to moderate acute pain
Dosage: CAPSULE;ORAL
ZIPSOR family patents
